Advertisement
Advertisement
U.S. markets open in 7 hours 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

First Wave BioPharma, Inc. (FWBI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.0900+0.0200 (+0.65%)
At close: 04:00PM EDT
3.1000 +0.01 (+0.32%)
After hours: 07:23PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close3.0700
Open3.0300
Bid0.0000 x 1000
Ask0.0000 x 1100
Day's Range3.0000 - 3.1880
52 Week Range2.7600 - 289.8000
Volume36,251
Avg. Volume567,515
Market Cap3.081M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-45.7800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FWBI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • First Wave BioPharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/16/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

    BOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into a definitive agreement with a certain institutional investor for the issuance and sale of 1,023,018 shares of common stock (or pre-funded warrants in lieu thereof) and warran

  • GlobeNewswire

    HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

    NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023. “Terry is an immensely valuable addition to our Board given her experience in business strategy, broad financial transactions and business development, and we

  • GlobeNewswire

    First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis

    Three U.S. clinical trial sites actively screening and enrolling patients; Topline data expected by mid-2023BOCA RATON, Fla., March 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that the second patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced ent

Advertisement
Advertisement